Please login to the form below

Not currently logged in
Email:
Password:

cell cancer

This page shows the latest cell cancer news and features for those working in and with pharma, biotech and healthcare.

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’ s Genetech nabs speedy review for Tecentriq in first-line breast cancer. ... The Swiss drug maker was hoping to gain another indication for Tecentriq in first-line non-small cell lung cancer (NSCLC), but it was unable to achieve a significant OS

Latest news

  • AZ says target of $45bn sales by 2023 still achievable AZ says target of $45bn sales by 2023 still achievable

    The cancer franchise was once again a standout, particularly Tagrisso (osimertinib) for EGFR-mutated non-small cell lung cancer (NSCLC) which grew 91% year-to-date and is now hitting the ... Lynparza (olaparib) for ovarian and breast cancer more than

  • Pfizer claims rapid FDA nod for Lorbrena Pfizer claims rapid FDA nod for Lorbrena

    Lorbrena (lorlatinib) is approved to treat patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), and is a follow up to Pfizer’s Xalkori, the first ALK inhibitor drug, ... inhibitor. “Over the years, Pfizer has transformed research,

  • Novartis: pipeline will generate 60 filings in three years Novartis: pipeline will generate 60 filings in three years

    interleukin-1 beta antibody for non-small cell lung cancer. ... 177. Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC).

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    Two-thirds of Keytruda’s sales come from non-small cell lung cancer (NSCLC), an indication in which Opdivo lost ground after a failed monotherapy trial in the first-line setting, ... that BMS’was the first company to have an immuno-oncology therapy

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led ... non-small cell lung cancer (NSCLC) trial.

More from news
Approximately 1 fully matching, plus 693 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    Other key launches will include Lynparza, its ovarian cancer treatment, now co-marketed globally with MSD. ... Its Imfinzi has secured the first-ever US and EU approval in locally- advanced, unresectable non-small cell lung cancer – a potentially

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but ... IQVIA’s Angela McFarlane, presenting her

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting, ”says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... It will also be interesting to see how gene

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics